Author

P. Giannatempo

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Lynch syndrome–associated urothelial carcinoma: clinical and molecular findings from a single-institution cohort

Lynch syndrome–associated urothelial carcinoma (LS-UC) is a rare and undercharacterized clinical entity. While FGFR3 alterations are well described in sporadic urothelial carcinoma, their prevalence and clinical implications in LS-UC remain unclear. We aimed to provide a comprehensive clinical and molecular characteriz...

A. Rametta, M. Barella, A. Scardino et al. · Familial Cancer · 0 citations

Aug 2026

Machine learning-integrated explainable artificial intelligence for survival prediction in urothelial carcinoma with enfortumab vedotin: an exploratory real-world analysis.

BACKGROUND Enfortumab vedotin (EV) has transformed treatment for advanced urothelial carcinoma (aUC), but outcomes vary. Machine learning (ML) with explainable artificial intelligence (XAI) may improve survival prediction. METHODS Data from 544 aUC patients receiving EV after platinum chemotherapy and immunotherapy (...

K. Sridharan, O. Fiala, G. Sivaramakrishnan et al. · Expert Opinion on Biological... · 0 citations